Brendan J. Kelly, MD

Infectious Diseases
Accepting new patients
Sees patients age 18 and up
MacGregor Infection Medicine and Travel Program
Make an appointmentCall 800-789-7366
Penn Medicine Provider

About me

  • Assistant Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
  • Assistant Professor of Epidemiology in Biostatistics and Epidemiology
  • Assistant Professor of Medicine in Microbiology

My education and training

  • Medical School: Columbia University
  • Residency: NewYork–Presbyterian Hospital
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English
Español
Spanish

Reviews

Average Rating

30 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2023
patient, kind, so intelligent. best doctor i've ever met
Anonymous
February 2023
he took time listened explained things
Anonymous
January 2023
we have a great connection
Anonymous
November 2022
i trust dr. kelly with a complicated problem

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Penn Medicine Rittenhouse Long-Term Acute Care Hospital
Dr. Kelly is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Monica Wei, Matthew J. Ziegler, Pam Tolomeo, Laura Cowden, Brendan J. Kelly k-mer sketch profiles identify suspected multidrug-resistant organism transmission events , European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 (Munich, Germany): 2026

Lucky CW, Medernach RL, Kelly BJ, Kwon JH, Woodworth MH. Microbiome Therapeutics for Clostridioides difficile Infection , Infect Dis Clin North Am, 39(4): 2025,663-683

Ziegler MJ, Anesi J, Tolomeo P, Glaser L, Cowden L, Cressman L, Huang E, Patel A, Lautenbach E, Pegues DA, Kelly BJ. Screening and targeted prophylaxis for Clostridioides difficile infection , Clin Microbiol Infect, 31(11): 2025,1907-1913

Laurel Redding, Scott G. Daniel, Joseph D. Zackular, Maho Okumura, Stephen D. Cole, Kyle Bittinger, Brendan J. Kelly Amplicon-Based Sequencing is Able to Accurately Detect Clostridioides Difficile , SSRN [preprint]: 2025

Ziegler MJ, Loughrey S, Bekele S, Huang E, Tolomeo P, David MZ, Lautenbach E, Glaser LJ, Kelly BJ. Comparative performance of sponge versus flocked swabs for culture-based and metagenomic detection of microbial contamination in the healthcare environment , Infect Control Hosp Epidemiol, 46(8): 2025,1-7

Sherrie Xie, Leigh Cressman, Matthew J. Ziegler, Brendan J. Kelly Impact of time post-hospitalization on carbapenem-resistance among Enterobacterales infections , European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025 (Vienna, Austria): 2025

Alyssa Mezochow, Emilia Wilkins, Leigh Cressman, Brendan J. Kelly Lung pathogens persist in the gut microbiome during critical illness , European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025 (Vienna, Austria): 2025

Kelly BJ, Kwon JH, Woodworth MH. Reply to Olle et al , J Infect Dis, 231(2): 2025,545

Ziegler MJ, Anesi J, Tolomeo P, Glaser L, Cowden C, Cressman L, Huang E, Patel A, Lautenbach E, Kelly BJ Screening and targeted prophylaxis for Clostridioides difficile infection: STOP-CDI. , Infectious Diseases Society of America, IDWeek. Oral Presentation; 2024 Oct; Los Angeles, CA.: 2024

Kelly BJ, Kwon JH, Woodworth MH. Escape Velocity-the Launch of Microbiome Therapies , J Infect Dis, 230(30): 2024,2-4

View all publications